EcoDrugPlus

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSUPAG00010012427
Gene Symbol: NR3C1
1 Cross references
278 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSUPAG00010021967
Gene Symbol: NR3C2
1 Cross references
212 Possible Orthologues:

Nucleophosmin 1

Ensembl ID : ENSUPAG00010022177
Gene Symbol: NPM1
1 Cross references
404 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSUPAG00010013810
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSUPAG00010020681
Gene Symbol: OPRD1
1 Cross references
252 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSUPAG00010003107
Gene Symbol: OPRK1
1 Cross references
262 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSUPAG00010015985
Gene Symbol: OPRM1
1 Cross references
214 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSUPAG00010003399
Gene Symbol: OPRL1
1 Cross references
199 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSUPAG00010022853
Gene Symbol: OXTR
1 Cross references
262 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSUPAG00010009510
Gene Symbol: PAK4
1 Cross references
163 Possible Orthologues:

Pancreatic Triacylglycerol Lipase

Ensembl ID : ENSUPAG00010023475
Gene Symbol: LOC113183009
2 Cross references
291 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSUPAG00010016258
Gene Symbol: PTH1R
3 Cross references
196 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).